

Filed on behalf of: GlaxoSmithKline LLC

By: Brian W. Nolan
Email: bnolan@mayerbrown.com
Tel: (212) 506-2517
Lisa M. Ferri (*pro hac vice* motion to be filed)
Email: lferri@mayerbrown.com
Tel: (212) 506-2340
Jonathan H. Kim
Email: jkim@mayerbrown.com
Tel: (312) 701-8592

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GLAXOSMITHKLINE LLC,
Petitioner

v.

FIBROGEN, INC.,
Patent Owner

Case IPR2016-01315
Patent 8,466,172

**DECLARATION OF LISA M. FERRI IN SUPPORT OF MOTION TO
APPEAR *PRO HAC VICE* ON BEHALF OF PETITIONER
GLAXOSMITHKLINE LLC**

I, Lisa M. Ferri, do hereby declare:

1. I am a partner in the law firm of Mayer Brown LLP and the head of the Intellectual Property group for the New York Office. I have over 20 years of experience as a patent litigator and trial lawyer, appearing and acting as lead counsel in numerous patent litigation matters before various United States District Courts and the U.S. International Trade Commission. I have also appeared on behalf of litigants before the U.S. Court of Appeals for the Federal Circuit, including as lead counsel. (See GSK Exhibit No. 1049). The majority of these cases have been within the technical field of the pharmaceutical and chemical arts.

2. I have served as an adjunct professor of law at Fordham University School of Law, where I teach Patent Litigation. Subsequent to graduating from law school, I served as law clerk to Chief Judge Edward D. Re, U.S. Court of International Trade, who sat by designation on a number of courts of appeal including the Federal Circuit.

3. I am familiar with U.S. Patent No. 8,466,172 (“the ‘172 patent”), which is at issue in this proceeding. I have served as lead trial and appellate counsel on several patent litigation matters for GSK and have been integral in advising GSK regarding the patent in this IPR. Given my involvement in counseling GSK concerning the ‘172 patent, I am familiar with the ‘172 patent, the

legal subject matter, technical subject matter, and prior art discussed in Petitioner's request for *inter partes* review of the '172 patent, which forms the basis for this proceeding. Further, considering my long history of advising GSK on patent matters, I am a trusted advisor of GSK.

4. I am a member in good standing of the Bar of the State of New York and the Bar of the State of New Jersey. I am admitted to practice before the United States Supreme Court, the United States Court of Appeals for the Federal Circuit, and several other appellate and district courts including the United States District Court for the District of New Jersey, the United States District Court for the Southern District of New York, and the United States Court of International Trade.

5. I have never been suspended, disbarred or sanctioned by any court or administrative body.

6. I have never had a court or administrative body deny my application for admission to practice.

7. I have never been sanctioned or cited for contempt by any court or administrative body.

8. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R.

9. I agree to be subject to the United States Patent and Trademark Office Code of Professional Responsibility set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

10. In the past three (3) years, I have applied for and been admitted *pro hac vice* in three *inter partes* review proceedings before the United States Patent and Trademark Office, *Ranbaxy Laboratories Ltd. et al., v. Vertex Pharmaceuticals Incorporated*, Case IPR2013-00024 (U.S. Patent No. 6,436,989), *Lupin Limited v. Vertex Pharmaceuticals Incorporated*, Case IPR2015-00558 (U.S. Patent No. 6,436,989) and *Sanofi-Aventis U.S. LLC and Regeneron Pharmaceuticals, Inc. v. Genentech, Inc. and City of Hope*, Case IPR2015-01624. I have also submitted *pro hac vice* motions in *Genzyme Corp. v. Genentech, Inc. and City of Hope*, Case IPR2016-00460, and *Lupin Limited v. Vertex Pharmaceuticals Inc.*, Case IPR2016-0558. Decisions on those motions are pending.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both,

Case IPR2016-01315
U.S. Patent No. 8,466,172

under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of U.S. Patent No. 8,466,172.

Dated: July 19, 2016

By: /s/ Lisa M. Ferri
Lisa M. Ferri